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Abstract
Cognitive impairment is one of the predominant diagnoses that in its early stages remain 
undetected in the primary healthcare setting. With Alzheimer's and dementia on the rise, 
it is paramount that cognitive impairment be detected promptly so preventative measures 
may be initiated to slow or avert progression of this dreaded disease. The annual 
wellness visit, a Medicare benefit added by the Affordable Care Act of 2010, 
recommends primary care providers conduct a screening to detect cognitive impairment 
during the course of this assessment. The Centers for Medicare and Medicaid services 
failed to recommend a specific screening tool to be utilized by primary care providers to 
detect cognitive impairment. The Medicare Detection of Cognitive Impairment 
Workgroup convened by the Alzheimer’s Association, conducted research on this 
subject, and found that the General Practitioner Assessment of Cognition (GPCOG), the 
Mini-Cog, and the Memory Impairment Screen (MIS) are brief structured tools that 
would be suitable for cognitive assessment function during the annual wellness visit. The
goal for this study was to evaluate 600 charts (100 from each primary care provider’s 
office) to determine if cognitive impairment screening was being conducted during the 
Medicare annual wellness visit. If the screening was being performed, further assessment 
was conducted to determine if  a recommended screening tool was utilized by the 
provider. The researchers have hypothesized that cognitive impairment screening is not 
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CHAPTER I 
Dimensions of the Problem
Cognitive impairment goes unrecognized in a large number of patients under the 
care of primary care providers. Delayed or missed diagnosis deprives affected 
individuals of available treatments and services that may help to improve their symptoms 
and help them maintain their independence (Cordell et al., 2013).
Alzheimer’s disease is the 5th leading cause of death among adults in the United 
States (U.S.) between 65 and 85 years o f age, and death rates for Alzheimer’s diseases 
are increasing—unlike death rates of other diseases such as cancer and heart disease 
which are on the decline (Centers for Disease and Prevention [CDC], 2016). Part of this 
growing problem is that cognitive impairment goes unrecognized in 27% to 81% of 
affected patients in primary care (Cordell et al., 2013). In 2013, around 5 million 
Americans were living with Alzheimer’s disease; by 2050 it is projected that this number 
will rise to 14 million (CDC, 2016). The annual wellness visit, a Medicare benefit added 
by the Affordable Care Act o f 2010, recommends primary care providers conduct an 
assessment to detect cognitive impairment (Cordell et al., 2013). The Centers for 
Medicare and Medicaid services did not recommend a specific assessment tool to be used 
by primary care providers to detect cognitive impairment. The Medicare Detection of 
Cognitive Impairment Workgroup convened by the Alzheimer’s Association conducted 
research on this subject and found that the GPCOG, Mini-Cog, and MIS are brief 
structured tools that would be suitable for cognitive assessment function during the 
annual wellness visit (Cordell et al., 2013). Thus, the problem addressed in this study 
was the cognitive impairment screening practices o f primary care providers in 
Mississippi.
As America’s population ages, the prevention of age-related diseases, such as 
Alzheimer’s and dementia, becomes paramount. Therefore, this study determined 
whether primary care providers are adhering to the national guidelines related to the 
screening of patients for cognitive impairment. If the screening process and procedures 
used by primary care providers in Mississippi related to cognitive impairment are found 
to be subpar, measures can be put into place to improve the screening process, which in 
turn will improve the lives of Mississippi’s aging population.
Purpose of the Research
The purpose of this study was to determine whether primary care providers are 
following the recommendations related to cognitive impairment screening during an 
annual wellness visit put into place by the Patient Protection and Affordable Care Act of 
2010 effective January 1, 2011.
Significance of the Research
By determining if healthcare providers are adhering to the recommendations 
related to screening for cognitive impairment, the current researchers will disclose if 
there is a lack of knowledge and awareness on the subject indicating the need for 
education of primary care providers. Prevention of disease and illness is one of the most 
important aspects of healthcare and a principal duty of healthcare providers. If detected 
in the early stages, mild cognitive impairment can be slowed by various interventions. 
Interventions, such as management of comorbidities and medications including Namenda 
and Aricept, can aid in slowing the progression from mild cognitive impairment to 
dementia and Alzheimer’s.
Oftentimes without proper screening of the early stage of cognitive decline, mild 
cognitive impairment goes undetected and the patient’s memory impairment is not
detected until it has progressed to dementia or Alzheimer’s disease. With sound 
screening practices, early detection of cognitive impairment is possible and in turn will 
result in more positive outcomes for patients and hopefully will decrease the prevalence 
of detrimental diseases such as dementia and Alzheimer’s.
Conceptual Framework
Healthcare providers can and should be present within the interpersonal 
environment of the client. One way of becoming personally involved with clients is to 
monitor for changes in health status with the use of screening tools. The purpose of 
medical screening is for the early detection of disease so that measures can be taken to 
prevent further decline or recognize the need for close observation as well as taking into 
consideration the safety of the patients. Nola Pender’s Health Promotion Model (HPM) 
was used as a guide in this study to determine if primary care providers are following the 
guidelines related to cognitive impairment screening during an annual wellness visit. 
Screening for cognitive impairment, dementia, and Alzheimer’s has become paramount 
due to the aging population of America. Early recognition of cognitive impairment 
through screening can assist the nurse practitioner (NP) in developing a care plan to treat 
early symptoms and possibly slow down or delay further decline. Drawing upon the 
concepts and constructs of the HPM, the researchers will be able to use a more holistic 
approach in caring for clients. Personal factors, such as age and self-motivation, help 
predict healthcare behaviors and willingness to participate in a personal health promotion 
plan. Recognizing perceived barriers such as fear of losing independence is important 
when promoting the early recognition of cognitive decline. The HPM assumes that 
healthcare professionals are part o f the client’s interpersonal environment and can 
influence the client throughout their life. Illuminating the need for cognitive impairment
screening each year during an annual wellness visit and applying education based on the 
HPM will assist our patients in overcoming perceived barriers related to a diagnosis of 
cognitive impairment and dementia.
Research Questions and Hypothesis
The following questions were developed to guide the research and data gathering.
1. During annual wellness visits, are primary care providers screening Medicare 
Patients 65 years and older to detect cognitive impairment?
2. During the cognitive impairment screening, are primary care providers using 
one of the three validated patient assessment tools: the General Practitioner 
Assessment of Cognition (GPCOG), the Memory Impairment Screen (MIS), 
Mini-Mental State Exam (MMSE), or the Mini-Cog when cognitive 
impairment screening is performed? If none of the above, which assessment 
tool are they using?
3. What interventions are put into place for patients who show a decline in 
cognition on these screening tools?
The research hypothesis was as follows: Primary care providers are not screening 
Medicare patients 65 years and older for cognitive impairment during an annual wellness 
exam.
Definition of Terms
There were various terms regarding research that require a definition to clarify 
their meaning in relation to the current study. The theoretical and operational definitions 
respectively follow:
Primary care provider
Theoretical: The health care provider to whom a patient first goes to address a 
problem with his or her health. (Venes, 2013)
Operational: Medieal eare provider performing the wellness exam.
Cognitive impairment
Theoretical: When a person has trouble remembering, learning new things, 
concentrating, or making decisions that affect their everyday life. (CDC, 2010)
Operational: Impairment of an individual’s mental function or capacity based on 
cognitive testing results.
Annual wellness visit
Theoretical: A physical exam performed by a primary eare provider once every 
12 months.
Operational: A yearly physical exam performed by a primary eare provider for 
people over the age of 65 years that is free to the patient and paid by Medicare.
Cognitive impairment screening
Theoretical: Screening for altered mental status thought process.
Operational: Screening for altered mental thought processes by the following 
tools: GPCOG, MIS, Mini-Cog, and Mini-Mental State Exam (MMSE).
Interventions
Theoretical: An action taken to enhance a situation such as a medical disorder.
Operational: An action taken to improve a medieal disorder, such as the 
following: neurological referral, social services referral, medications for dementia, and 
psychosocial work-up.
Assumptions
For the purpose of this study, the following assumptions were made:
1. The researchers assumed primary eare providers are aware of guidelines to 
perform cognitive screening at Medicare annual wellness exams to all patients 
65 years and older.




The researchers presented a review of literature which included research articles 
that examined Nola Pender’s Health Promotion Model (HPM). Data that supported the 
findings applicable to the current study of cognitive impairment screening practices were 
also included in the review of literature. To gain perception for the current study, the 
researchers reviewed Nola Pender’s work to help give insight of the HPM.
Literature Related to Conceptual Framework
The role of the nurse practitioner has evolved since the time of inception in the 
1960s. Rural communities continue to desire the eare and attention afforded by nurse 
practitioners and their availability to provide healthcare within reach of those who would 
otherwise lack access to convenient and affordable medieal care (Keeling, 2015). Nurse 
practitioners are involved in promoting and maintaining healthy lifestyles and preventing 
disease and, therefore, need to understand the influences that can hinder health promotion 
in order to motivate their patients to adhere to management programs. Health promotion 
is a process of being proactive in the preservation of the health and well-being of patients 
and society. The HPM, developed by Nola Pender in the 1980s, assists the NP with 
several areas of health promotion. The model gives nurses a structural format of 
definitions and concepts that can help design health promotion strategies. Use of this 
theoretical framework helps predict how certain behaviors and practices can have an 
influence on health outcomes.
Studies on illness prevention and health promotion have been a focus o f research 
for many years. In a eross-seetional survey of 388 residents of northern Illinois 
performed in 1978, it was shown that 64% of those surveyed indicated interest in using
an illness prevention and health promotion service if provided by a nurse practitioner.
The results of the study showed a high level of acceptance of nurse practitioners and 
indicated the need within the community for nurse practitioners to provide prevention and 
health promotion centered eare (Pender & Pender, 1980). According to Pender, health 
promotion is a goal for today’s healthcare just as disease prevention was a component of 
healthcare before the 20th century. Pender believes the patient should play an active role 
in managing his or her health by desiring to change or alter certain lifestyles that may 
contribute to disease. Nola Pender’s view also included the concept that past behavior, 
cultural traditions, and family traditions can impact a person's ability to engage in health- 
promoting behaviors. Pender’s HPM provides healthcare providers with a tool that helps 
them understand how the consumer can be motivated to attain better health (Alligood, 
2014).
Promoting healthy behaviors is part of the nurse practitioner’s role while earing 
for clients. Self-efficacy is the belief that one has in oneself to accomplish a goal. A 
perceived benefit is an anticipated positive outcome which a client believes will result 
from a health behavior. Educating clients using Pender’s HPM can result in increased 
self-efficaey and perceived benefit with subsequent increase in positive affect. Dehdari, 
Rahimi, Aryaeian, and Gohari (2013) conducted a quasi-experimental study based on 
Pender’s Health Promotion Model in 2011 to determine the effectiveness of nutrition 
education interventions in improving the frequency and nutrient intake of breakfast 
consumption among female students. The constructs of Pender’s model were used to 
develop a questionnaire that included questions related to prior behaviors, perceived self- 
efficaey, and perceived barriers to name a few. Perceived barriers can be either imagined 
or actual blocks and personal costs related to taking part in certain behaviors. A Likert
rating scale was used to record answers. The results of the questionnaire were then used 
to design a nutrition education intervention. Usual classroom nutrition education was 
provided to each of two groups: an experimental group and a control group. The 
experimental group received extra nutritional education based on Pender’s HPM. Results 
of the study indicated that the experimental group had increases in perceived benefit and 
self-effieaey. Perceived barriers and negative activity-related affect were decreased as 
well in the experimental group. Increasing perceived self-efficacy results in having fewer 
perceived barriers in performing certain healthcare behaviors, thus changing the client’s 
perceptions on health behaviors and leading to positive changes (Dehdari et al., 2013).
Managing chronic disease is another important role of the nurse practitioner. The 
NP uses theory in everyday practice while applying knowledge, education, and skills to 
promote the health of his or her clients. One of the most common chronic diseases that 
NPs manage is hypertension. As a significant health concern, hypertension is the leading 
risk factor for heart disease, stroke, and renal disease. Lifestyle modifications, including 
diet changes, weight management, increasing physical activity and managing stress, will 
help control hypertension and prevent long-term complications. Hussein, Salam, and 
Amr (2016) utilized a quasi-experimental study to assess the management of 
hypertension using the Pender’s HPM. The model was used because it focuses on the 
relationship between individual eharaeteristics and experiences, behavior specific 
cognitions, and behavioral outcomes. Another reason the model was used is the 
assumption that people are active in maintaining healthy behaviors and are willing to 
change their environment to support these behaviors. The study was divided into a study 
group and a control group. Results of the study indicated that nursing education 
interventions were successful in improving knowledge, lifestyle behaviors, and
measurements in blood pressure among the adults whieh were in the study group as 
opposed to the control group (Hussein et al., 2016).
Healthcare providers can and should be present within the interpersonal 
environment of the client. One way of becoming personally involved with clients is to 
monitor for changes in health status with the use of screening tools. The purpose of 
medical screening is early detection of disease so that measures can be taken to prevent 
further decline or recognize the need for close observation as well as taking into 
consideration the safety of the patients. Pender’s HPM was used as a guide in a study 
that proposed to determine if primary care providers are following the guidelines related 
to cognitive impairment screening during an annual wellness visit. Screening for 
cognitive impairment, dementia, and Alzheimer’s has become paramount due to the 
aging population of America. Early recognition of cognitive impairment through 
screening can assist the NP in developing a eare plan to treat early symptoms and 
possibly slow down or delay further decline. Drawing upon the concepts and constructs 
of the HPM, the researchers will be able to use a more holistic approach in caring for 
clients. Personal factors, such as age and self-motivation, help predict healthcare 
behaviors and willingness to participate in a personal health promotion plan. 
Recognizing perceived barriers such as fear of losing independence is important when 
promoting the early recognition of cognitive decline. The HPM assumes that healthcare 
professionals are part of the client’s interpersonal environment and can influence the 
client throughout their life. Illuminating the need for cognitive impairment screening 
each year during an annual wellness visit and applying education based on the HPM will 
assist patients in overcoming perceived barriers related to a diagnosis of cognitive 
impairment and dementia.
Impact of the Problem
An extensive review of literature was conducted to substantiate the necessity for 
further research related to Mississippi’s PCPs regarding screening practices for cognitive 
impairment. The review of literature encompassed the effects of various comorbidities, 
consequences of use of certain pharmaceuticals, and the relationship of laboratory studies 
related to cognitive impairment. This literature review validated the need for more 
extensive research.
The current researchers found studies that support the need for Vitamin B12, 
Vitamin D, and GFR to be assessed during patients’ annual wellness visit. Patients with 
diagnoses of depression and hypertension are more susceptible to develop cognitive 
impairment or have a more rapid progression of the disease process.
According to Eastley, Wilcock, and Bucks (2000), it is standard practice to screen 
for reversible causes of dementia; however, it is unknown what the effects of vitamin 
B12 deficiency actually are on cognition. Vitamin B12 deficiency makes up a very small 
percentage of reversible dementias. Previous studies have shown that B12 supplements 
do not improve cognitive function or prevent cognitive decline. Therefore, according to 
previous research, vitamin B12 deficiency does not cause or enhance dementia.
However, minimal research exist on the effects of B12 on cognitive impairment or 
cognitive decline.
The goal of this research was to determine if vitamin B12 supplementation can 
improve cognition or if it can prevent cognitive decline in demented patients or in 
patients with cognitive impairment. Eastley et al. (2000) attempted to prove that Vitamin 
B12 treatment in non-demented patients will yield improvement of cognitive function.
No theoretical framework was identified for Eastley et al.’s (2000) study.
The sample consisted of 1,432 patients previously assessed at the Bristol Memory 
Disorders Clinic between 1985 and 1998. The retrospective study divided patients into 
two groups: (a) those with diagnosis of dementia and (b) those with no diagnosis but with 
cognitive impairment. Numerous neuropsychological assessments were performed on the 
sample, including the Mini-Mental State Examination, the Weehsler Adult Intelligence 
Seale, and the Verbal Fluency Test. The patients who were treated with B12 replacement 
therapy and who had a second assessment after treatment were matched for age and 
diagnosis with patients whose B12 levels were within normal range upon the initial 
examination. The differences in test scores pre-B12 therapy and post-B12 therapy were 
compared to the test scores of the first and second visits for the matched group. Data 
between the two groups were compared using ehi-square and independent t tests (Eastley 
et al., 2000).
Upon first assessment of the patients {N=  1,432), 125 patients had B12 values 
that were below the normal range. At the follow-up appointment 7-10 months later, 6 
patients refused follow-up appointments, 9 patients did not return for follow-up, and 4 
patients had their appointments cancelled by their residential homes. In addition, 3 
patients were followed up by another facility, and 2 patients died before their follow-up 
appointments. Therefore, 101 patients were seen for follow-up assessment. However, of 
these, 4 did not receive B12 therapy because the level was just below normal and then 
normal upon return, and charting was not available on 9 other patients (Eastley et al., 
2000).
Of the patients classified as dementia patients treated with B12 supplementation, 
none of them improved in all areas of cognitive testing. However, the patients did 
improve minimally in memory testing and verbal fluency. The patients that were
matched who were not treated with B 12 therapy deteriorated slightly—but not enough for 
statistical significance.
In the patients who had no dementia diagnosis but were cognitively impaired, the 
results were different (Eastley et al., 2000). The group who were treated with vitamin 
B12 had a statistical significance of improvement on the verbal fluency section of the 
assessment, while the matched group deteriorated. Further, before the B12 therapy, the 
scores for the verbal fluency test scores on the patients to be treated were much lower 
than the matched group upon the initial assessment. In addition, 2 patients had 
improvement on all areas of the testing after the B12 therapy. Therefore, in patients with 
minimal cognitive impairment, cognitive function may be improved with vitamin B 12 
therapy. However, in patients with dementia, there does not seem to be a benefit of 
vitamin B12 replacement.
Eastley et al. (2000) stated that further investigation is needed on vitamin B12 
deficiency in regard to cognitive decline. According to Eastley et al. (2000), more 
research is needed to confirm the fact that B 12 therapy may improve cognitive 
impairment, especially in the frontal lobe and language function. Eastley et al. suggested 
that a larger prospective study be conducted to determine if the results are able to be 
reproduced.
There were numerous problems of missing data throughout the research by 
Eastley et al. (2000). This is partly due to the fact that this was a retrospective study, and 
data were either lost or never charted. For some of the testing, portions of the results 
were not available. It is unknown whether portions of the testing were refused by 
patients, were never given due to severity of cognition, or because of physical disability.
In addition, because of the elderly population, medication changes, deaths, or
institutionalization also eliminated portions of the data. Therefore, what seemed to be an 
initially large sample size was decreased drastically (Eastley et al., 2000).
These data apply to the current researchers’ study which focused on identifying 
cognitive impairment early and treating any deficiencies. If cognitive impairment can be 
determined early and a patient is vitamin B12 deficient, then it is possible that 
supplementation of vitamin B12 could help to improve frontal lobe and language 
functioning on cognitive screening assessments. This research shows that nurse 
practitioners need to be drawing lab work and attempting to treat any deficits in order to 
catch cognitive impairment early and work on slowing its progression. The current 
researchers were able to add B12 deficiency to the tool for the research project in order to 
detect cognitive decline based on B12 deficiency.
Littlejohns et al. (2014) used a quantitative design to determine if low vitamin D 
concentrations are associated with increased risk for all-cause dementia and Alzheimer 
disease. This is concerning due to the high rates of vitamin D deficiency in older adults 
and the unknown causes of cognitive impairment. No theoretical framework was 
identified in the study (Littlejohns et al., 2014).
The hypothesis of the study was to determine if vitamin D is neuroprotective.
The enzyme that synthesizes the biological effect of vitamin D and the vitamin D 
receptor are both found in the brain. Studies have been shown via in vitro that vitamin D 
helps increase clearance of amyloid plaques by increasing action of macrophages. 
Amyloid plaques are formed along with neurofibrillary tangles. These plaques and 
tangles cause damage that is associated with Alzheimer’s disease.
Elderly ambulatory participants free from dementia, cardiovascular disease, and 
stroke were seleeted from the Cardiovascular Health Study held between 1992-1993 and
1999 with a sample size of 1,658. Serum samples were collected in 1992-1993 for 
determination of serum 25-hydroxyvitamin D (25(OH)D) concentrations with the use of 
liquid chromatography-tandem mass spectrometry. Verification by SRM 972 from the 
National Institute of Standards and Technology was used to test the calibration of the 
serum 25(OH)D. In 1998-1999, a group of appointed neurologists and psychiatrists 
assessed the participants on the basis annual cognitive assessments by utilizing repeat 
MRI scans, medical records, questionnaires, and proxy interviews. According to the 
criteria of National Institute of Neurological and Communicative Diseases and 
Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS- 
ADRDA), incident all-cause dementia and Alzheimer’s disease were diagnosed 
(Littlejohns et al., 2014).
After collection and analysis of the data, the results confirmed that vitamin D 
deficiency is associated with an increased risk of all-cause dementia and Alzheimer’s 
disease. Participants who were vitamin D deficient (> 25 nmol/L to < 50 nmol/L) or 
severely deficient (< 25 nmol/L) were at a higher risk for development for both all-cause 
dementia and Alzheimer’s disease. There was about a 51% increased risk for the 
participants that were deficient; however, there was a 122% increased risk for the 
severely deficient individuals. In this study (Littlejohns et al., 2014), there were few 
cases of vascular dementia due to the exclusion of cardiovascular disease and stroke 
patients.
The biggest strength of this research by Littlejohns et al. (2014) was the diverse 
population size and included white and African-American men and women. Secondly, 
the researchers also used an immensely thorough methodology approach. On the other 
hand, the biggest weakness was that not all types of dementia were studied. Littlejohns et
al. (2014) stated that there was the need for conduction of further research consisting of 
CVD and stroke patients; stroke risks are also associated with low vitamin D levels. 
There were very few cases of incident vascular dementia due to the exclusion of CVD 
and stroke patients.
In conclusion, the results of Littlejohns et al. (2014) established that vitamin D 
deficiency and the increased risk for all-cause dementia and Alzheimer disease are 
associated. Multiple processes linking subnormal vitamin D levels and risk for dementia 
were established. Areas that involved memory, such as the hippocampus and dentate 
gyrus, included vitamin D receptors. Also, the enzyme that synthesizes the active form 
of vitamin D is made in many regions of the brain; Vitamin D ’s active form regulates 
neurotrophin expression and the survival, development, and function of the neural cells. 
This research by Littlejohns et al. (2014) was very useful to the students’ current research 
as it identified the need for the assessment of patients with vitamin D deficiency to be 
screened for cognitive impairments in primary and or acute care clinics. Littlejohns et al. 
(2014) correlated to the students’ research question and helped in expanding the 
knowledge needed in determining screening patients for cognitive impairment by 
screening patients for Vitamin D.
Darsie et al. (2014) conducted a study to evaluate the association of kidney 
function and cognitive impairment. Recent evidence has proven that decreased kidney 
function is associated with cognitive impairment and declines in cognitive impairment. 
Previous studies used creatinine as a means for measuring kidney function. Darsie et al. 
felt that this was not the best way to evaluate kidney function due to the effects that aging 
and decreased muscle mass had on creatinine. Darsie et al. found that Cystatin C was the 
best way to evaluate kidney function because these levels are not affected by muscle
mass changes of the elderly. Therefore, Darsie et al (2014) considered it reasonable to 
evaluate Cystatin C levels and performance of cognition using the Modified Mini-Mental 
State Examination (3MS) to determine the effects kidney function had on cognition. 
There was no mention of a basis for theoretical framework in this study (Darsie et al., 
2014).
Recent findings suggested that poor kidney function and cognitive impairment 
were associated, and they were linked to an increased risk of death. Due to the past 
findings, Darsie et al. (2014) sought to further evaluate the link between poor kidney 
function and cognitive impairment and their influence on death. During this study,
Darsie et al. hypothesized that “baseline cystatin C-based kidney function would be 
associated with a decline in cognitive function and cognitive impairment free life years 
(CIFLYs) and that these associations would be mediated by clinical cardiovascular 
disease” (p. 69).
Darsie et al. (2014) examined the relation of kidney function and cognitive 
impairment of 3,907 participants in four U.S. communities in California, Maryland,
North Carolina, and Pennsylvania. Participants meeting criteria of being 65 years old or 
older, not institutionalized, remaining in the community for 3 years or longer, and not 
receiving treatment for cancer were examined in the study. The participants were 
evaluated annually during in-person visits from 1992 to 1999 using interviews and 
physical examination. Blood specimens were drawn to evaluate serum cystatin C to 
estimate yearly glomerular filtration rates (GFR), and the 3MS was administered to 
monitor cognitive function. “Age, sex, race, smoking status, and educational level were 
determined by self-reports at baseline. Hypertension was assessed at baseline using self-
reports and prescription medication. Blood pressure and diabetes were assessed annually” 
(Darsie et al., 2014, p. 70).
Darsie et al. found that 20% of those studied had a GFR of < 60, 62% had a GFR 
of 60-89.9, and 18% had a GFR of 90 or higher. Participants with a higher GFR generally 
were younger, female, se lf  reported nonwhite race, had a higher level of education, never 
smoked, had a lower body mass index, and were less likely to have hypertension. Those 
with a higher GFR also had higher scores on the 3MS. The study showed that 
participants with a GFR of < 60 and those between 60-89.9 had faster declines in the 
3MS compared to those with higher GFRs. Those with a GFR of < 60 proved to have a 
lower average of life-years compared to those with a GFR of 90 and above. They also 
had fewer CIFLYs than those with a higher GFR. To validate Darsie et al.’s reasoning of 
using cystatin C instead of creatinine to evaluate GFR, they found that GFR based on 
creatinine failed to find a significant difference in the decrease in 3MS per year. In 
Darsie et al.’s study of the community dwelling elderly, they found that kidney function 
elevated by cystatin C was associated with the level and change in cognitive function 
over the 6 years of study. Also noted throughout the study was the fact that those with a 
decreased baseline GFR had a greater decline in predicted cognitive function. “Reduced 
kidney function was also associated with fewer CIFLYs” (Darsie et al., 2014, p. 73).
One strong suit of Darsie et al. (2014) was the study was conducted over a period 
of about 7 years. This period of time afforded ample time to draw conclusions and facts 
and ascertain if what they hypothesized would prove to be correct. Darsie et al. also used 
a very large population size which enabled results to be generalized. Darsie et al. 
indicated a limitation of their study was the limited length of follow-up. The study was 
based off annual visits which did not include follow-up information.
Darsie et al. (2014) was useful in the student researchers’ study for validation of 
evaluating patients GFR, especially those estimated by cystatin C, and the relation to 
those with cognitive impairment. In gathering this information from Darsie et al. (2014), 
the student researchers were able to determine if the results could be replicated as they 
were evaluating those 65 and older as well. The student researchers evaluated whether 
cognitive impairment screenings are being done and what chronic diseases those with 
cognitive impairment have, such as decreased kidney function.
Review of literature has been completed to support the need of assessing hearing 
impairment and smoking status. Hearing loss and cognitive decline show a strong 
correlation and needs attention in assessing risks for cognitive impairment. Smoking is 
linked to cognitive impairment in later stages of life.
Deal et al. (2015) compared hearing loss, hypertension, and the use of hearing 
aids with cognitive decline. The background and significance of the study revealed that 
hearing impairment is prevalent, modifiable, and has been associated with cognitive 
decline. No theoretical framework was identified in Deal et al. (2015).
Data were obtained from a pilot study carried out in a subset of participants from 
the Atherosclerosis Risk in Communities Study (ARIC) to test the hypothesis that, 
compared with participants without hearing impairment (HI), participants with HI in 
older age have poorer cognitive performance, measured by multiple cognitive tests, both 
cross-sectionally at the time when hearing is measured and longitudinally, when a faster 
rate of 20-year change in cognitive functioned measured from midlife to older age. They 
hypothesized that, among participants with HI, those with hearing aids have slower rates 
of cognitive decline than those with HI who do not use hearing aids (Deal et al., 2015).
The ARIC study is a population-based prospective cohort study of 15,792 men 
and women between 45 and 64 years of age recruited in 1987-1989 from 4 U.S. 
communities (Washington County, MD; Forsyth County, NC; Jackson, MS; and 
Minneapolis, MN). The participants returned for a 5th ARIC visit in 2011-2013. A pilot 
study on hearing was initiated at the Washington County site in 2013, and audiometric 
testing was offered to 307 participants at their checkup. Six declined participation, and 
46 did not complete the examination (45 because of impacted cerumen in one or both 
ears). Since only 2 participants were nonwhite, analysis was restricted to self-reported 
whites, resulting in an analytical sample of 253. Participants were older with an average 
age of 77.1 years and more likely to have a high school education or less. Following 
informed consent, a comprehensive neuropsychological battery was administered. The 
following domains were included: (a) Memory-Delayed Word Recall Test (DWRT) (7), 
Incidental Learning Test (8), and Logical Memory Test I and II (9); (b) Language-Word 
Fluency Test (10), Animals Naming Test (11), and Boston Naming Test (12); and (c) 
Processing speed/attention-Digit Symbol Substitution Test (DSST) (13), Digit Span 
Backwards Test (13), and Trail Making Test Parts A and B (14-15) (Deal et al., 2015).
Pure tone air conduction audiometry was conducted in a sound-treated booth in 
2013. Thresholds in each ear were obtained by standard octaves from 0.5 kHz to 8 kHz 
by trained technicians using insert earphones. Hearing impairment was as follows: 
normal < 25dB, mild 26-40 dB, and moderate/severe > 40dB). Only 5 participants had 
severe HI. Hearing aid use was self-reported.
Demographic information was collected in 1987-1989, including age (years), sex, 
and education (< 12 years and >12 years). Smoking was recorded as ever or never. 
Hypertension (19) was considered present if diastolic > 90mm Hg, systolic ^  140mm Hg,
or if medication was taken for hypertension. Diabetes (19) was defined as BG >126 
fasting, > 200 nonfasting, or medication taken or medical diagnosis recorded. Depressive 
symptoms were measured in 1990-1992 using 7 items that relate to depression from the 
21 -item Maastricht Questionnaire, which assesses vital exhaustion. Items were scored as 
0 = No, I = Don't know, and 2 ^  Yes and summed to yield a possible score ranging from 
0 to 14, with higher scores indicating depressive symptoms.
Of 253 participants, 73 (29%) had no HI, 95 (37%) had mild HI, and 85 (34%) 
had a moderate or severe HI. Mean age at the time of the assessment was 76.9 years, and 
58.9% of participants have a high school education or less. On average, participants with 
moderate/severe HI were older (79.4 years) and more likely to be male (54%) and have 
hypertension at baseline (33%) than participants with mild or no HI. Mean test scores for 
memory, language and processing speed/executive function were poorest for participants 
with moderate/severe HI and best for participants with no HI. Among the 85 participants 
with moderate/severe HI, 51% reported using a hearing aid. Compared with hearing aid 
users, nonusers were more likely to have hypertension and diabetes.
The results demonstrate that moderate/severe HI measured in late life was 
associated with poorer concurrent memory performance and with a faster rate of prior 20- 
year decline in both memory and global cognitive function. HI has also been 
hypothesized to be a causal risk factor for cognitive decline, increased social isolation 
and loneliness, increased cognitive load, and changes in brain structure. Social isolation 
is associated with physiological changes, such as increases in systolic blood pressure and 
increased glueocorticosteroid levels, which could in turn impact brain structure and 
cognitive decline (Deal et al., 2015).
Limited study participants consisted of only whites from Washington County,
MD (Deal et ah, 2015). Additionally, there were no data on duration of HI.
There is a strong correlation between hypertension, DM, hearing loss, and 
cognitive decline. Deal et al. (2015) was a good foundation for the student researchers in 
comparing patients with hearing impairment and correcting that to cognitive decline.
Rusanen, Kivipelto, Quesenberry, Zhou, and Whitmer (2011) attempted to 
determine if there is any relation to smoking, particularly during mid-life, and the risk of 
dementia, including AD and vascular dementia (VaD). It is well-known that smoking 
causes cancer, increases risk for cardiovascular illnesses, increases respiratory distress, 
and increases risk for stroke. However, when smoking has been studied in relation to 
Alzheimer’s disease and dementia, there are conflicting results. While the few studies 
conducted are controversial, some studies show that smoking can even reduce the risk of 
cognitive impairment. No theoretical framework was used as a basis for this 
investigation.
Rusanen et al. (2011) expected to find results similar to the results of dementia 
findings in previous studies and see dementia in older people with fewer years of 
education. In addition, Rusanen et al. expected to find that women have a higher 
percentage of dementia. According to previous studies, the incidence of smoking and 
dementia is greater in African Americans than in the white or Asian populations.
Rusanen et al. (2011) expected to see this trend as well as a predisposition to VaD due to 
smoking with increased risk for stroke associated with smoking.
The sample consisted of every participant between 50 and 60 years of age who 
completed a Multiphasic Health Checkup in San Francisco and Oakland, CA, between 
1978 and 1985. The Multiphasic Health Checkup was completed by patients who
participated in a voluntary health examination at a Kaiser Permanente facility in northern 
California. When electronic dementia diagnosis was available in 1994, the records were 
pulled of those patients who were still alive and still members of the health plan, which 
included 21,123 people of varying race, age, and sex. If the smoking status was not 
included in the initial exam, the participants were excluded (Rusanen et al., 2011).
On the initial Multiphasic Health Checkup, the patients were asked numerous 
questions regarding their health status and family history. They were asked their 
smoking status of never, former, or current smokers, and current smokers were asked to 
quantify their smoking habits. The current smokers were divided into < 0.5 packs per 
day, 0.5-1 packs per day, 1-2 packs per day, and > 2 paeks per day. Comorbidities, such 
as diabetes, hypertension, hypercholesterolemia, cardiovascular disease, and strokes, 
were recorded from the beginning of data collection to the end of data collection.
The diagnosis of dementia was obtained through medical records from 1994-2008 
as either AD, VaD, or unspecified dementia diagnosed by a neurologist or a 
neuropsychologist. SAS 9.1 was used to perform all statistical analyses. 
Sociodemographic and clinical characteristics were compared using the chi-squared test. 
The Cox proportional hazards model was used to determine if there was relationship 
between midlife smoking and diagnosis of dementia, AD, or VaD. Incidence rates were 
determined by age categories of younger than 77, 77-81, 81-85, and older than 85 years 
(Rusanen et al., 2011).
After a mean follow-up of 23 years, 5,367 people were diagnosed as having 
dementia. More women than men were diagnosed. Participants were also older with 
fewer years of education, and more African Americans had the diagnosis as well. There 
was a higher percentage of divorced, widowed, or separated people with dementia than
those who were married, and a higher percentage of people who had never drank alcohol 
were diagnosed. A higher BMI in midlife and numerous comorbidities were also found 
in those diagnosed with dementia.
As for smoking, there was a drastic increase in dementia, AD, and VaD noted for 
the individuals who smoked > 2 packs a day during midlife compared to nonsmokers.
The increase in risk was less significant in the other smoking categories, and negligible in 
the former smokers or < 0.5 packs per day. Stroke was found to be highly associated 
with smoking and the risk for dementia. The risks for dementia, AD, and VaD were 
found to increase as the amount o f cigarettes smoked on a daily basis during midlife 
increased. This research study by Rusanen et al. (2011) is important in an attempt to 
identify risk factors for dementia, AD, and VaD and help to prevent the occurrence later 
in life.
Rusanen et al. (2011) indicated a need for further research to determine the 
cerebrovascular and neuropathologic changes that smoking causes in the brain which lead 
to dementia. Rusanen et al. encouraged further investigation to indicate smoking as a risk 
factor instead of a risk predictor for dementia.
The major strength of Rusanen et al. (2011) was the longitudinal aspect. The 
same patients were able to be studied 20-30 years after initial health examinations. 
Therefore, their entire health history had been recorded prior to any diagnosis of 
dementia or any outward signs of dementia which strengthens the end results and leads to 
internal validity.
One weakness noted in Rusanen et al. (2011) was the way the age brackets of 
diagnosis were broken down. When there are categories that overlap, it is impossible to 
know in which category each result will be placed. For example, the age groups were <
77 years old, between 77-81 years old, 81-85 years old, and then > 85 years old. There 
was no way to know where the 81 -year-olds were placed because they overlapped into 
two categories. In addition, the category age was > 85 years old, but it should have been 
86 years old and above, so as not to be confused where to put the 85-year-olds. Another 
weakness that the researchers stated was the diagnosis of dementia. Some patients were 
diagnosed as AD, some as VaD, and some with no specification. All patients were 
diagnosed by neurologists or neuropsychologists, but the difference in diagnosis 
techniques and how they were diagnosed were unknown.
The current student researchers focused on early detection of cognitive 
impairment and the implications o f screening practices by practitioners. Since this 
research indicated that the more a person smokes in midlife, the higher the correlation of 
dementia diagnosis later in life, it was important for the student researchers to also 
investigate whether practitioners are obtaining a smoking history and educating on the 
evidence-based findings o f the potential of AD and VaD later in life. This smoking 
history, in addition to yearly cognitive screenings, could help diagnose early dementia, 
which can be treated to slow the progression of the disease in patients.
Goldstein, Levey and Steenland (2013) used a prospective longitudinal cohort 
design to identify if high blood pressure levels are associated with a more rapid decline in 
particular cognitive domains. No theoretical framework was identified for this study. 
Detection of a correlation between hypertension and progression of cognitive decline is 
crucial for advancement in primary care prevention of cognitive impairment. It is 
projected by the year 2050 that 15 to 18 million people 60 years old and over age group 
will develop dementia, 70% of these individuals will also have a diagnosis of 
hypertension. Various studies have been conducted in the past that have raised
controversy on the link between cognitive impairment and hypertension, and some of the 
studies found an association while others failed to find a correlation. The National 
Institutes of Health (NIH) found that many of these studies were inadequate due to the 
procedures utilized for defining cognitive impairment and the methods employed for 
diagnoses of hypertension. Despite the errors in some previous studies, Goldstein et al. 
(2013) noted that there was a great deal of encouraging findings related to employing 
lifestyle changes in prehypertensive and hypertensive adults to decrease their blood 
pressure which in turn resulted in improved psychomotor speed, memory, and executive 
function.
Goldstein et al. (2013) comprised a study to determine if there was an association 
between elevated blood pressure and decline in individuals with cognitive impairment 
over a 2-year period. It was hypothesized that the participants diagnosed with mild 
cognitive impairment who presented with high blood pressure readings according to 
hypertensive guidelines on more than one occasion over the two-year period would suffer 
a more rapid overall cognitive decline than those with normotensive levels. Goldstein et 
al. sought to develop a study that would delineate with greater exactitude the 
interconnection of hypertension and cognitive decline. The participants in the study had 
a definite diagnosis of mild cognitive impairment and the comorbidity of hypertension.
To achieve a more reputable and reliable study, participants underwent multiple 
neuropsyehological tests as opposed to a single measure. To better diagnose true 
hypertension, the blood pressure levels of participants were examined at annual follow-up 
visits instead of reliance on a single baseline visit.
Participants (N = 1,385) in Goldstein et al.’s (2013) study were diagnosed with 
mild cognitive impairment. Information for the study was collected as part of the
Uniform Dataset, a data protocol maintained by the National Alzheimer’s Coordinating 
Center. Participating organizations included 31 National Institute on Aging Alzheimer’s 
Disease Centers nationwide. The recruitment strategies utilized by the Alzheimer’s 
Disease Center’s varied participants could come from the clinics themselves or be 
members of the local community. Inclusion criteria remained the same for all 
participants. Each participant had to be diagnosed with mild cognitive impairment by a 
clinician at the center and have no recent history or diagnosis of stroke or transient 
ischemic attack (TIA). To assess the current overall functional status and cognitive 
function of participants, the Clinical Dementia Rating Sum was conducted on each 
participant. Baseline blood pressure readings and readings for at least two subsequent 
follow-ups were also required of participants. The participants were monitored over the 
course of 3 yearly visits. At each visit, systolic and diastolic blood pressures were 
obtained with the participant in a seated position, and neuropsychological testing was 
conducted to assess for any changes in cognitive function.
To establish whether there was a difference in cognitive funetion over time 
between those with high and normotensive blood pressure readings, researchers 
conducted a longitudinal linear regression analyses. Of the 1,385 participants, 15% had 
high blood pressure readings on all three occasions, and 23% had high readings on two 
the three occasions, 27% had one high reading, and 35% had no high readings. When 
neuropsychological test results were evaluated, the performance of participants with high 
readings on two to three occasions significantly declined on visuomotor sequencing, set 
shifting, and naming. There were no significant negative outcomes detected in the 
participants that had normotensive blood pressure or those with one occasion of
high blood pressure. The implications of these research outcomes support association 
between high blood pressure and risk of cognitive decline in those with cognitive 
impairment (Goldstein et al., 2013).
The biggest strength related to Goldstein et al.’s (2013) study was that the study 
addressed and corrected methodological problems mentioned in recent reviews related to 
this type of study. The researchers achieved this by not relying on self-reported 
diagnoses of hypertension by participants that can often be inaccurate, as the participants 
may have never been truly diagnosed with hypertension by a healthcare provider.
Instead, Goldstein et al. (2013) referenced actual systolic and diastolic readings. 
Goldstein et al. further solidified their research by not basing their statistics on a single 
reading at one point in time. On the other hand, weaknesses can be found within this 
study including duration of follow-up period and reliance on an established database. A 
longer duration of study would allow researchers to identify if the relationship between 
hypertension and cognitive decline persisted over time. Extended duration of study 
would also allow researchers to study how profound the effect of uncontrolled blood 
pressure is on cognitive impairment over the course of a greater part of the participant’s 
lifespan. The reliance on an established database limited this study as well. The 
researchers recognized this weakness and stated that there were possibly many 
mechanisms through which elevated blood pressure could affect cognitive decline. 
Goldstein et al. (2013) recommended further research where these associations could be 
better studied with a mediation model or a longitudinal study.
Richard et al. (2012) used a cohort study of a multiethnic community to evaluate 
the association of late-life depression with mild cognitive impairment and dementia. 
There was no theoretical framework identified in this study. Depression and the
progression or increased risk of cognitive impairment have been long reported in 
prospective studies conducted in a memory clinic setting, but no association has been 
found in population-based studies.
Richard et al. (2012) noted that inconsistencies existed in previous studies that 
attempted to correlate late-life depression with incident dementia and the studies that 
sought to evaluate depression and mild cognitive impairment. With the undertaking of 
this new cohort study, Richard et al. sought to resolve and clarify a number of the 
inconsistencies published in prior studies.
These researchers composed a study that consisted of 2,183 participants. The 
participants were composed of healthy individuals over the age of 65 years who were 
Medicare eligible. The participants resided in low-income neighborhoods situated in 
northern Manhattan. The participants were selected by systematic random sampling 
based on ethnicity and age group. Ethnicities included, Hispanic, non-Hispanic, blacks, 
and whites. Age groups were classified as 65-74 years old and >75 years old. 
Participants were excluded from the study if they had been previously diagnosed with 
dementia by a physician. A baseline visit was conducted where the participants were 
evaluated using neuropsychological testing for dementia and screening for depression 
using the short version of the Center for Epidemiological Studies Depression scale. A 
score on the scale > 4 indicated a diagnosis of depression in individuals. The 
neurophysiological testing was then administered at subsequent follow-up visits at 
intervals of 18 and 24 months.
Richard et al. (2012) concluded that there is an association of depression with 
prevalent mild cognitive impairment, but depression does not precede or cause cognitive 
impairment in itself. In turn, the researchers did discover that there is a link that
correlates depression and the progression of mild cognitive impairment to dementia. 
Richard et al. stated that at baseline there were 320 participants diagnosed with a form of 
mild cognitive impairment, 160 with amnestic mild cognitive impairment, and 160 with 
non-amnestic mild cognitive impairment. Of the 320 individuals, 67 progressed to 
dementia. Richard et al. discovered that participants with a dual diagnosis o f depression 
and mild cognitive impairment were at twice the risk to develop dementia when 
compared to the participants with mild cognitive impairment that lacked depressive 
symptoms.
Richard et al. (2012) did not directly speak to the need for future research in their 
study but did recognize limitations that could be addressed in future research studies.
The limitations recognized by the researchers included that the Centers for 
Epidemiological Studies Depression Seale only inquired about depressive symptoms 
experienced within the last 2 weeks. Limiting the individual's experience of depressive 
symptoms to such a short span of time could overlook those who have experienced 
depressive symptoms in the past but not within the given timeframe. Richard et al. also 
stated that they did not explore all possible explanations for the relationship between late 
life depression and dementia, such as the possibility that depression could affect the 
threshold for dementia to become manifest. A weakness not addressed by the researchers 
regarding their study was the selection of participants. The study used participants from 
a predominantly low-income neighborhood. The use of participants with poor economic 
status raises the question that their incidence of depression could be somehow linked to 
their socioeconomic status and current living conditions. The study by Richard et al.
(2012) could be recreated in the future with a broader participant base and with 
participants from multiple socioeconomic levels.
The greatest strength of Richard et al. (2012) was that the researchers assessed 
depression and mild cognitive impairment over a span of 3 subsequent visits which 
allowed time for change and progression to be analyzed. In addition, the inclusion of 
multiple ethnicities was a strength of this study. The researchers included persons from a 
variety of ethnic backgrounds—allowing a wider range of analysis. Furthermore, the 
exclusion of patients with prior physician diagnosis dementia added to the validity of the 
study (Richard et al., 2012).
In conclusion, Richard et al. (2012) was useful in the review of literature for the 
current student researchers’ study on primary care providers’ detection of cognitive 
impairment during the annual wellness visit. The research by Richard et al inferred that 
depression does not precede cognitive impairment, yet it does accompany it and often 
hastens the progression of mild cognitive impairment to dementia. The student 
researchers can use this information as part of the tool used in evaluation of cognitive 
impairment screening by providers. Having the research supporting this correlation 
indicates the need for adequate and thorough evaluation of patients with mild cognitive 
impairment and accompanying comorbidities such as depression. Richard et al.’s (2012) 
study revealed the need to promptly assess those positive for mild cognitive impairment 
for any depressive symptoms to detour faster and further advancement of cognitive 
impairment. Preventive strategies, such as medication management, teaching, and 
counseling can be put in practice to slow the progression of decline and treat patients’ 
accompanying depression, thereby enabling the patient to live a more fulfilling and 
happier life while maintaining their current state of cognition for a longer period of time.
Certain medications need to be assessed along with polypharmacy to help primary 
care providers assess for risks of cognitive impairment. Other medications that need to
be analyzed is the use of anticholinergics as they are associated with increased risk for 
dementia. Heavy use of opioids have been examined to support the need for cognitive 
impairment screening.
Gray et al. (2015) conducted a population-based longitudinal study of persons 65 
years and older to examine the association between long-term cumulative anticholinergic 
use and increased risk for dementia. Anticholinergics are used frequently by older adults 
for the treatment of overactive bladder, seasonal allergies, depression, and COPD. 
Significance of this study was to provide a possible association with the cumulative use 
of anticholinergics in the elderly to increased risk for dementia, thus leading to increased 
awareness among healthcare providers of this potential association. No theoretical 
framework was mentioned in this study.
Gray et al. hypothesized that higher cumulative use of anticholinergics would be 
associated with increased risks of dementia. Another hypothesis was that if an 
association was based solely on treating prodromal symptoms, then the association would 
be found for antidepressants but not for other anticholinergic classes.
The study was conducted on participants from the Adult Changes in Thought. 
(ACT) study. The ACT is an ongoing longitudinal study of older adults in the Seattle area 
that focused on ways to delay or prevent dementia. All members of the ACT study were 
members of Group Health (GH) whieh is an integrated healthcare delivery system. The 
participants were 65 years or older and were randomly sampled from the GH members. 
None of the participants had dementia upon entry, and all participants had been in the GH 
health system for 10 years prior to beginning the study. At least one follow-up visit post­
enrollment was required. Of the 4,724 participants in the ACT study, 3434 were eligible
for the present study. The analysis of this study included participant data through 
September 30, 2012.
The Cognitive Abilities Screening instrument was used to screen for dementia 
upon entry into the study and at each biennial study visit. Scoring ranges were from 0- 
100; the higher the score, the better the cognitive performance. T hose scoring 85 or less 
were then evaluated for dementia using physical assessment and neurologic assessment. 
Those that were diagnosed with new-onset dementia had at least one annual follow-up 
examination to confirm the dementia diagnosis. Hazard ratios and 95% confidence 
intervals for the association between anticholinergic use and dementia were estimated 
using the multivariable Cox proportional hazards regression models.
Data (the drug name, strength, route of administration, date dispensed, and 
amount dispensed) were collected from a computerized pharmacy dispensing system. 
Examples of medications commonly prescribed included chlorpheniramine, doxepin, 
oxybutynin, meclizine, and olanzapine. A total medication dose was calculated for each 
prescription filled, and then a standardized daily dose was calculated in order to create 
exposure measures. Cumulative use was categorized ranging from no use to > 3 years. 
The heaviest level of exposure was reached if participants took any of the mentioned 
medications for more than 3 years.
Gray et al. (2015) found that 78.3% of the participants had at least one refill for an 
anticholinergic during the 10 years before study entry. More than 90% of the 
anticholinergics used were antidepressants, antihistamines, and bladder antimuscarinics. 
During follow-up of 7.3 years, 797 of the 3,434 eligible participants (23.2%) developed 
dementia. Of these, 637 (79%) developed Alzheimer’s disease. Those in the highest 
exposure category with a standardized daily dose > 1,095 showed a notable increase in
the risk for dementia (adjusted HR, 1.54 [95% Cl, 1.21-1.96]) eompared to those with no 
use of anticholinergics. This analysis statistically supported the first hypothesis that 
higher cumulative use of anticholinergics would be associated with increased risk of 
dementia. The findings of Gray et al. (2015) proposed that primary care providers need 
to be aware of the possible association of cumulative anticholinergic use and the 
increased risk for developing dementia. Decreasing anticholinergic use is a potentially 
modifiable risk factor to developing dementia.
Gray et al. (2015) identified several strengths of the study. Using computerized 
pharmacy data, they were able to describe medication use 10 years prior to enrollment. 
The researchers were able to look at medications by drug class, which allowed 
comparison of effects between drug classes. The researchers excluded prescriptions that 
were filled within the most recent 1 -year period, thereby eliminating protopathic bias. A 
large community-based sample and a mean follow-up of > 7 years were additional 
strengths of the study. Weaknesses included the fact that some first-generation 
antihistamines are available as over-the-counter medications and may lead to 
misclassification of exposure. Also, reliability was based on prescriptions filled but did 
not guarantee that the medication was administered. Gray et al. (2015) suggested the 
need for further studies to better understand whether dementia is gradually reversed after 
discontinuing therapy.
The findings of Gray et al. (2015) provide a strong basis for screening to detect 
cognitive impairment during the Medicare annual wellness visit. This yearly “wellness” 
visit was designed for the beneficiary of Medicare to develop or update a personalized 
plan along with the primary care provider to assist in preventing disease and disability as 
well as early detection of changes in cognition. Identifying risk factors and conditions
that can benefit from evidenced-based interventions are included in the annual wellness 
visit. Based on the findings of this study, primary care providers need to be aware of the 
risk for dementia with cumulative use of anticholinergics. Medication review and update 
are included in each annual wellness visit as well as assessment for cognitive impairment 
which can assist both provider and beneficiary to work together in creating a personalized 
prevention plan and detection of cognitive impairment or dementia.
Dublin et al. (2015) used a quantitative design to determine if prescription opioids 
increased risk for dementia or cognitive decline which is concerning due to the high 
percentage of prescription opioid use among the elderly population ages 65 years and 
older. Delirium may be caused by opioid use which, in turn, may increase the risk for 
dementia. Sedation is one cognitive side effect of opioids. Neuropathological changes 
have been shown in young adult, drug abuser autopsies similar to those of AD.
Microglia, the immune cells in the brain that mediate inflammation, are modulated by the 
effects of opioids. These effects may lead to neurodegenerative changes that cause 
cognitive impairment. Opioids also stimulate eell death of mieroglia and neurons. This 
evidence supports the theory that long-term opioid use may contribute to decline in 
cognition. No theoretical framework was used in this study.
The hypothesis of Dublin et al. (2015) was to determine if accumulative exposure 
and more recent opioid use would be associated with higher risk of impaired cognition. 
The examination between prescription opioid use and risk of dementia or impaired 
cognition was the goal of this study.
Dublin et al.’s (2015) study consisted of 3,434 participants, aged 65 years and 
older, without dementia. The participants were selected from GH, an integrated 
healthcare delivery system based out of Seattle, Washington. The participants were
enrolled with GH for a minimum of 10 years to ensure sufficient data on long-term 
medications. The participants were selected between 1994 and 1996. From 2000 
through 2003 and in 2004 an expansion cohort was also recruited. The Cognitive 
Abilities Screening Instrument (CASI) was completed every 2 years and continued until 
September 30, 2012. The CASI results ranged from 0-100. Individuals scoring 86 or 
lower went through further evaluations by a study physician and neuropsychological 
testing. If the patient was diagnosed with dementia, he or she would be reevaluated in 
one year to confirm the diagnosis. The goal was to look for a more rapid cognitive 
decline versus individuals that have not developed dementia or cognitive impairment. 
Therefore, participants were excluded with a diagnosis of dementia because it would 
have skewed the results of this study. Computerized pharmacy information was used to 
identify prescription opioid use, including drug name, strength, route of administration, 
number of pills, and date dispensed. The medications were converted to morphine 
equivalent portions using factors of conversion. Total standardized doses (TSDs) were 
calculated from the morphine conversions forming the calculation that one TSD = 30mg 
of morphine. Nonsteroidal anti-inflammatory drugs (NSAIDs) are medications that may 
be used for treatment o f pain and may be considered as therapeutic as opioids. NSAIDs 
use was also evaluated in this study as a seeondary analysis. NSAIDs were categorized 
as 0 to 60, 61 to 180, 181 to 540, or 541 or more TDSs. The heaviest exposure of 
ibuprofen was by using 1,200 mg daily for about 1.5 years.
The results of Dublin et al. (2015) suggested the participants with the heaviest 
opioid (>91 TSDs in the past 10 years) or NSAID (> 541 TSDs) use had slightly higher 
dementia risk than participants with little or no use. However, a more rapid cognitive 
decline with opioid use was not associated. Moderate use of opioids and NSAIDs were
not associated with dementia risks. The participants with the heaviest use of opioids 
were a little older and mostly female. They were also more likely to have an increase in 
comorbidities (e.g., obesity, self-rated health as poor or fair, and depressive symptoms) 
and were unlikely to participate in exercise than individuals with little or no use of 
opioids.
Strengths of Dublin et al. (2015) were the large population size and detailed 
pharmacy database. The study of long-term medications provided sufficient material to 
Dublin et al. (2015). However, due to the fact that NSAIDS are over-the-counter, self- 
reporting of medications must have been assessed periodically. The small increase in risk 
for cognitive impairment of heavy use of opioids needs further attention. Heavy 
accumulative use of opioids may truly increase the risk for dementia. The fact that the 
need for heavier use of opioids may be due to the state of poorer health compared to the 
participants with little or no use. Other cofactors may not have been examined and 
accounted for in the study. Other studies have suggested that structural brain changes 
may be due to chronic pain, including a global decrease in gray matter volume and 
density, particularly in the areas of the brain that are related to pain processing.
In conclusion, the results of Dublin et al.’s (2015) study established that the 
heaviest use of opioids had a slight increase in risk for dementia. This is useful in the 
student researchers’ study because it helps identify the need for primary care providers to 
assess for opioid use in conjunction with polypharmacy. Evaluating polypharmacy is an 
intervention needed to help eliminate risk factors for cognitive impairment.
The tools used to assess cognitive function need to be analyzed if primary care 
providers are performing the screenings. The following study by De Gobbi Porto et al. 
supports the need for assessment so patients can be treated to slow progression of the
disease. De Gobbi Porto et al. support the fact that most patients do want to have their 
Medicare annual screening performed.
De Gobbi Porto et al. (2013) used a quantitative design to evaluate the diagnostic 
accuracy of cognitive screening tests to differentiate mild cognitive impairment from 
subjective memory complaints. De Gobbi Porto et al. developed a scoring system 
derived from the tests to aid in improving the ability of healthcare providers to 
differentiate between the two conditions. No theoretical framework was identified for 
this study. Complaints related to memory problems are a frequent occurrence in primary 
care, and providers often find it difficult to differentiate between patients with mild 
cognitive impairment and those that are subjective memory complainers. Patients with 
mild cognitive impairment present with subjective complaints of cognitive decline that 
are accompanied by objective decline in neuropsychological evaluation, yet due to their 
preservation of functionality they do not yet meet the criteria for diagnosis of dementia. 
Mild cognitive impairment may be due to degenerative diseases or psychiatric disorders. 
It can also represent the transitional state between cognition of normal aging and the 
development of dementia. In contrast, subjective memory complainers present in clinics 
with subjective complaints of cognitive decline as well but do not display decline upon 
neuropsychological evaluation. Multiple interventions have been identified that 
significantly slow the progression of mild cognitive impairment to dementia, which 
makes early diagnosis paramount. Cognitive screening tools are essential in the 
differentiation between mild cognitive impairment and subjective memory complaints; 
therefore, diagnostic accuracy and scoring related to these tests are imperative to proper 
diagnosis.
De Gobbi Porto et al. (2013) identified methods of neuropsychological testing 
used in primary care, the Mini-Mental State Examination (MMSE) and the Brief 
Cognitive Battery Examination (BCB). The researchers then added delayed recalls in the 
MMSE and a phonemic fluency test of letter P fluency (EPF). A score was then created 
for these tests that they hypothesized would be capable of discriminating between mild 
cognitive impairment and subjective memory complaints.
This study by De Gobbi Porto et al. (2013) was conducted on volunteers from the 
local community over the age of 60 years who spontaneously expressed complaints of 
cognitive decline upon completion of a memory complaint questionnaire. For 
preliminary evaluation, the participants were submitted to clinical evaluation using the 
MMSE, BCB, EPF, and delayed recall. Participants were then screened with the 
Geriatric Depression Scale (GDS), Geriatric Anxiety Scale (GAS), and the Functional 
Activities Questionnaire (FAQ). The researchers then used these scores to exclude 
patients who scored > 4 on the FAQ and > 5 on the GDS. Participants believed to have 
dementia, those with active neuropsychiatrie conditions, those with conditions that could 
have affected their cognitive performance, and participants with < 8 years of formal 
education were excluded from the next round of neuropsychological testing. The 
remaining eligible participants were tested further with vision and verbal tests 
administered by an experienced neuropsychologist.
After collection and statistical analysis of data, the results revealed that, out of a 
total of 106 participants, 32 were found to be subjective memory complainers, and 74 
were found to have mild cognitive impairment. The results established that a score 
acquired from screening tests can distinguish with moderate to good accuracy between 
mild cognitive impairment and subjective memory complainers. The MMSE, LDR,
delayed recall of BCB, and LPF showed a statistically significant difference between the 
two groups. The researchers then calculated the highest average of the sum between 
sensitivity and specificity to determine the best cut-off score for each test and added 
together final scores of all tests creating an overall final score. The implications of the 
research outcomes in this study are very important to advancing development in testing 
for cognitive impairment in primary care.
The biggest strength related to this study was the selection of screening tests used 
to evaluate the participants. The screening tests utilized can be conducted easily with 
minimum training or supplies in a timeframe of < 15 minutes, which is ideal for the often 
fast-paced setting of primary care. On the other hand, several weaknesses can be found 
within this study, including population, sample size, and selection of participants. With 
such a small sample size totaling 106 participants, it is unclear if this is an adequate 
representation of the population. The criteria that had to be met by participants including 
lack of certain disease processes and education level greatly limited the study as well— 
excluding a vast number o f individuals such as those suffering with depression and those 
who only obtained low levels of education. De Gobbi Porto et al. (2013) acknowledged 
these weaknesses and recommended that further study be conducted in a different 
population with a larger number of subjects and varied education levels.
In conclusion. De Gobbi Porto et al. (2013) was useful in the review of literature 
for the current student researchers on cognitive impairment. The current research and 
methodology varied, yet the assessment of primary care providers and their use of 
appropriate screening tools for the early detection of cognitive impairment were the 
central focus in the research as well. This study also emphasized the direct association 
between early detection of true cognitive impairment and prompt implementation of
preventive strategies to help slow the disease process of dementia. Results obtained from 
this study and the researchers’ own suggestions for further studies in different and larger 
populations validate that there is need for more in-depth and continued research related to 
the detection of cognitive impairment in primary care.
Eichler et al. (2015) performed a quantitative study that sought to address the 
effect of screening for cognitive impairment in primary care practices and the subsequent 
formal diagnosis rate of dementia. The significance of this study was to show that a 
considerable amount of patients may go undiagnosed without the use of cognitive testing 
tools and that recognizing cognitive impairment in older patients due to screening could 
result in a proactive stance in initiating adequate treatments earlier in the disease process. 
No theoretical framework was identified within this study.
No hypotheses were clearly stated in Eichler et al. (2015), but several statements 
throughout the study pointed to the apparent questions the researchers were attempting to 
answer. Eichler,et al. mentioned implementation of the annual wellness visit for 
Medicare used in the United States that includes assessing for any cognitive change and 
also the proactive dementia case finding scheme in the United Kingdom which was 
implemented with the aim of improving the diagnosis rate of dementia, thus improving 
the care o f these patients. With no recent data on screening for dementia in Germany, 
Eichler et al. sought to contribute empirical findings to the effect of a screening test for 
dementia in German primary care clinics on the rate of formal diagnoses. The 
researchers also aimed to contribute findings to the distribution of etiologies of newly 
assigned diagnoses as well as factors that could be associated with positive dementia 
screening and formal diagnosis of dementia.
A cross-sectional analysis was performed on data gathered from the ongoing GP- 
based, randomized, controlled intervention trial. The trial is known as the DelpHI-MV. 
This trial, which consist of an intervention and control group, was designed to test the 
efficacy and efficiency of implementing a subsidiary support system for persons with 
dementia who live at home. Eligibility for the study was based on age > 70  years old and 
living at home. Eligible patients were then screened at GP-practices using DemTect, 
which is a personal interview-based tool that includes five tasks: (a) recall of a word list, 
(b) number transcoding task, (c) work fluency task, (d) digit span reverse, and (e) a 
delayed recall of word list. The DemTect helps in deciding whether cognitive 
performance is adequate for age (13-18 points) or whether MCI (9-12 points) or dementia 
(8 points or below) should be suspected. A DemTect score of < 9  was part of the 
inclusion criteria. The patients that met these criteria were informed about the study by 
their GP and were invited to participate. Upon agreeing to participate, they were required 
to provide written informed consent. An ethics committee approved the informed 
consent. Study enrollment began January 1,2012. The participants were then assigned 
to an intervention or control group which was dependent upon randomization to an 
intervention or control group of the GP-practice. The intervention group received the 
DelpHI-intervention, the independent variable; and the control group received care as 
usual. Of the 4,064 patients that were screened at 108 participating GP-practices, 692 
patients were eligible for the DelpHi trial. Of these, 406 agreed to participate in the 
study. Another 163 patients were then excluded for various reasons, such as not starting 
the baseline assessment, death, or relocation. Preliminary data, which included the 
completed baseline assessment regarding relevant variables, were available on January 1, 
2014, for the 243 patients that remained. From this group, 97 (40%) had already been
diagnosed with dementia before the screening. Analysis of the study was based on data 
from 146 patients that had not received a formal diagnosis of dementia before screening. 
The German version of the MMSE for cognitive status, the Geriatric Depression Scale, 
and the Bayer Activities of Daily Living Scale were the instruments used along with 
demographic data, including age, sex, and living situation to describe the sample.
Descriptive statistics were used to summarize the socioeconomic and clinical 
characteristics of the study sample. Patients were categorized into two groups: patients 
that were diagnosed with dementia after screening and patients that were not diagnosed 
with dementia after screening. Of the 146 patient sample, 74 were not formally 
diagnosed and 72 were formally diagnosed with dementia. The analysis suggested favor 
of screening for dementia. The overall diagnosis rate of dementia increased from 40% 
before screening to 70% after screening. The study analysis revealed that 74% of those 
that were formally diagnosed were women. The statistics further illustrated that 
cognitive impairment scores from the MMSE were lower for women when compared to 
the total sample score. This factor should be implicated in the need for further research 
and studies based on screening practices of primary care providers.
Eichler et al. (2015) identified some concerns in the study. First, screening could 
result in potential harm. Older patients may avoid seeing their doctor for fear of being 
diagnosed with dementia; and, second, a false-positive screening could cause 
misdiagnosis resulting in anxiety and depression in the affected patients. Discussion was 
provided on future research including further implementation of screening procedures for 
differential diagnoses.
Eichler et al. (2015) was included in this literature review for the present research 
on cognitive impairment screening practices of primary care providers in Mississippi in
that the analytical results indicated that a considerable number of patients that do have 
some degree of cognitive impairment are not being recognized based on primary care 
visits where a screening tool is not used. The results provided evidence that routine 
screening can help to increase the diagnosis rate of dementia considerably which will 
lead to better outcomes for many patients. The significance of this study related to the 
current study in that it is concerned with the problem that dementia and Alzheimer’s 
disease goes unrecognized in a large number o f patients while under the care of a primary 
care provider. The present study was guided by Neuman’s Systems Model which focuses 
on the client as a whole system.
Fowler et al. (2012) used a cross-sectional design to determine patients’ 
perceptions and willingness to undergo screening for dementia in primary care settings. 
Over 4 million Americans are affected by dementia which is an incurable degenerative 
neurological disease. The United States Preventative Services Task Force recommends 
there is no evidence to uphold the screening for dementia by primary care providers 
because of insufficient evidence to support if screening is beneficial, harmful, or 
effective. The goal of Medicare annual visits is to prevent disease, and one of the nine 
elements consists of cognitive impairment screening. Patients’ perceptions of cognitive 
screening may be viewed as harmful or beneficial, while gathering data to grasp patients’ 
thoughts of dementia screening may reflect the outcome goals of wellness screenings by 
primary care providers. No theoretical framework was identified in this study.
The hypothesis of Fowler et al. (2012) was to determine the relationship between 
patients’ perceptions and their readiness to be evaluated for dementia. The proposed 
explanation was that patients who viewed harm in being screened were more likely to 
refuse screening versus individuals who viewed screening as beneficial. The Perceptions
Regarding Investigational Screening for Memory in Primary Care Questionnaire 
(PRISM-PC) designed by researchers at Indiana University Center for Aging Research 
was an instrument utilized in the initial screening process to capture viewpoints of 
individuals’ perceptions of dementia screening.
Participants aged 65 years and older with no documented diagnosis of dementia 
were approached by research assistants from the Indiana University Practice Based 
Research Network between January 2008 and June 2009. The selected participants 
received healthcare services from a primary care community-based system in 
Indianapolis, IN. Study participants signed an informed consent. The PRISM-PC 
domains consisted of the following: (a) acceptance of dementia screening, (b) benefits of 
dementia screening, (c) stigma of dementia screening, (d) negative impact of dementia 
screening on independence, (e) suffering related to dementia screening, (f) screening for 
other conditions, and (g) beliefs related to treatment for Alzheimer’s disease.
After completion of the PRISM-PC, 89.7% of participants agreed to undergo 
screening for dementia by a written test. The MMSE or the Community Screening 
Interview for Dementia (CSI-D) was given to each individual. Of the 497 (89.7%) 
initially screened, 63 (12.7%) screened positive for impaired cognition. The analysis 
proved that the only significant variance of accepting or declining screening was in the 
age range. Ages 70-79 years was the age range most likely to decline screening due to 
loss of autonomy. They were also the age range that would mostly benefit from 
screening.
The results of this study established that most of the participants were willing to 
be screened for dementia. The refusal rate was higher in individuals aged 70 to 79 years 
old. PCPs should be educated about the prevalence of the refusal in this age range.
Education to this age group will allow the patients a clearer understanding of the 
available interventions to decrease or prevent cognitive impairment. Interventions PCPs 
may include in their assessment for prevention or treatment of cognitive impairment 
include the following: (a) eliminating certain medications that increase the risk for 
cognitive impairment (e.g., Oxybutynin), (b) checking labs such as Vitamin D (as we 
know that low vitamin D levels increase plaque formation in the brain), and (c) 
completion of dementia screenings at a younger age are
Coutinho, Drummond, Teldeschi, and Mattos (2016) attempted to determine if the 
level o f awareness regarding memory deficits is helpful in distinguishing between 
depression and cognitive impairment. Inaccurate reports of memory loss or cognitive 
status is a major challenge for memory clinics. Clients tend to overestimate or 
underestimate their own cognitive status, thus creating inaccuracies. Therefore, it is 
important to determine if a client is suffering from major depressive disorder (MDD) 
before a diagnosis o f mild cognitive impairment (MCI) is made. Discriminating the 
differences between cognitive concerns and a true cognitive decline is essential in 
diagnosis and treatment of cognitive impairment. No theoretical framework was 
identified for this study.
Coutinho et al. (2016) attempted to determine if there is a difference in personal 
cognitive assessment between those with MDD and those who do not suffer MDD. In 
addition, the question of whether one group will perform better on the objective memory 
testing was raised. The hypothesis of the study was that clients with MDD would have 
more complaints of memory loss than clients without MDD but would reveal normal 
cognitive performance.
Coutinho et al. (2016) compared memory performance on objective testing, the 
extent of memory complaints, and the level of self-awareness of memory deficits. Of the 
63 patients, 38 were women and 25 were men. All participants were 61-86 years old 
seeking evaluation because of memory concerns. The subjects of this study were 
evaluated using the Geriatric Depression Scale (GDS) and the Mini-Mental State 
Examination (MMSE) in a private memory clinic. All patients were diagnosed as either 
MDD or MCI by a board-certified psychologist using the DSM-5 criteria. Those patients 
without MDD or MCI diagnosis were used as a control group of elderly with healthy 
cognition. Age and years of formal education were similar in all three groups. Direct 
questioning about memory complaints and concerns were asked on a questionnaire to 
determine a self-report of memory status. Subjects then performed the Rey Auditory 
Verbal Learning Test (RAVLT) to determine actual cognitive impairment. Level of 
awareness was calculated by self-reported memory appraisal versus performance of the 
RAVLT. To compare demographic, neuropsychological, and self-reported variables, 
ANOVA testing was used. Effect size was determined by using eta squared. A 2-tailed 
significance threshold was used for all statistical tests.
The level of awareness between the MCI group and the control group did not 
differ; however, the awareness between MDD and MCI subjects was significant. The 
MDD subjects underestimated their memory functioning but performed well on their 
memory testing. The MCI subjects overestimated their cognitive performance but scored 
lower on their memory testing. This testing proves that depression can cause an 
alteration in a subjective memory analysis. Therefore, self-report of cognitive 
impairment is not always reliable, and an objective memory test must also be performed.
Coutinho et al. (2016) provided a limited sample size, with more subjects in the 
control group than in either of the groups being studied. There were 25 subjects in the 
control group, only 16 in the MDD group, and 22 subjects in the MCI group. While the 
data are still adequate, a larger sample size would enhance the relevance of the study.
The researchers including educational background and age limits were necessary for 
adequate comparison of subjects. It is also beneficial that the subjects did not know they 
were performing in a research study, which could have altered or skewed the data.
While Coutinho et al.’s (2016) study does not directly relate to the current 
research project, it was definitely a valuable resource. It is important to note that neither 
the subjective nor the objective memory testing alone is an adequate tool to determine 
MCI. The current researchers assessed data based on an objective memory test. In 
addition to a practitioner performing an objective memory test, it was important to see if 
a self-report memory test is completed as well.
Bayley et al. (2015) conducted a study with the purpose to report experience with 
a large nationwide public memory screening program. The background and significance 
of the study were detection of cognitive impairment being the first step for determining 
whether an individual needs further assessment for significant memory disorder or 
dementia. No theoretical framework was identified for this study.
The following research questions were not clearly stated in the study;
1. Is community-based screening a good tool for assessing cognitive 
impairment?
2. Is this screening tool more or less effective in the community setting or 
general practitioner's office?
3. Do age, gender, and education level play a comparative role in cognitive 
impairment?
4. Should other factors such as family members and friends be involved in the 
study?
The study was conducted in local community sites. The information compiled 
for this report consisted of 4,396 participants. Of these participants, 1,257 were male and 
3,109 were female. The ages ranged from < 35years old to > 85 years old. Highest 
education levels were elementary, high school, > high school, bachelor's degree, and 
post-bachelor's degree. Races were White, Black, Hispanic, or other.
The participants volunteered for the study. Upon arrival to the site, participants 
were given a voluntary participant survey with 29 questions which included the 
following: (a) demographic characteristics, (b) medical history, (c) reasons for attending 
the screening, (d) preferences for where to conduct the screening, (e) concerns of beliefs 
about memory, and (f) their current activities to help reduce the risk for dementia. Each 
site was set up to conduct one of the 7 well-validated dementia screening tools. The tools 
were the Mini-Cog, General Practitioner Assessment of Cognition (GPCOG), Memory 
Impairment Screen (MIS), Kokmen Short Test of Mental Status (STMS), Mini-Mental 
State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and the Saint 
Louis University Mental State Examination (SLUMS). These tools met the criteria for 
screening. They were validated, easy to administer, no cost, relatively free o f education, 
race, or cultural bias, and took 5 minutes or less to administer.
A private room was set up for each screener, and each test adhered to a standard 
format. Each site was responsible for time and location of screenings, selecting the 
appropriate healthcare professionals to obtain information, selecting their screening test.
distributing and collecting all data forms, emphasizing confidentiality, publicizing the 
event, encouraging participants with screening scores below cutoff to follow up with their 
healthcare provider, and distributing additional education material.
Overall, 11.7% failed one of the 7 screening tests. Failure rates were higher in 
older and less-educated participants. Subjective memory concerns were associated with 
40% greater failure rate for persons of similar age and education but no memory 
concerns; 88.1% of the participants were told that they did not have memory problems 
detectable with the tests used. On the survey given before the screening, the question 
"Are you concerned about your memory?" 11% answered no, with 8.2% failing the 
screening. Because the individuals did not sign consent, data were collected 
anonymously. Birthdates were not collected, and age was reported in broad 10-year 
increments. Also, the study may have been more biased since participants were aware of 
study beforehand and may have had concerns with memory loss. The scientists were 
overall happy with this study; however, there were a few recommendations for future 
studies. The first would be too involved third-party participation who were aware of 
participants' levels of daily function. Secondly, the participants would be given a 
tracking number for declines in scores over time to determine whether screening led to 
appropriate support, education, and other resources. There would also need to be a way 
to ensure that follow-ups were conducted with these patients and their primary healthcare 
providers.
Holsinger et al. (2012) performed a study to determine specificity and sensitivity 
of four screening instruments used to detect cognitive impairments and dementia in 
primary care. It has been predicted that the prevalence of cognitively impaired patients 
will drastically increase in the elderly population in the coming years. A nationwide
study determined that 14% of those patients 70 years and older had dementia. Cognitive 
impairment without dementia (CIND) and mild cognitive impairment accounted for 6% 
to 22%; out of those with CIND, 12% later developed dementia. Holsinger et al. (2012) 
sought to pursue this study based on the prevalence of missed or undiagnosed cognitive 
impairment and dementia in primary care. No theoretical framework use was mentioned 
in this study.
In finding that primary care providers wanted more information on the validity of 
screening tools, Holsinger et al. (2012) took four screening tools and determined their 
accuracy of detecting cognitive impairments and dementia. The researchers wanted to 
determine if the brief tools screened as well as longer tools. The modified Mini-Mental 
State Examination (3MS), Memory Impairment Screen, Mini-Cog, and a two-item 
functional memory screen were the tools studied. The 3MS and the Mini-Cog had the 
highest accuracy of detection in this study. The 3MS used in this study was a modified 
version of the Mini-Mental State Exam. It was designed to better assess memory, verbal 
fluency, similarities, and delayed recall (Holsinger et al., 2012). The Mini-Cog is a brief 
screening tool used to assess memory and recall and uses the Clock Drawing Test.
The study was conducted using three primary care clinics of veterans. There were 
630 participants who were aged 65 years and older and had no previous diagnosis of 
dementia or psychotic illness in their medical record. Of the 630 participants, most were 
male with an average age of 74.8 years. The participants were sampled at random in one 
of the three primary care clinics. A blinded research nurse performed the interviews and 
provided the screening tools to participants. Medical history was also documented with 
screening information, such as cardiac function, stroke, head injury, and substance abuse
(Holsinger et al., 2012). Previous findings have suggested that depression is associated 
with dementia and was also evaluated with the study.
Holsinger et al. (2012) found that 21 participants met criteria for dementia and 
247 for CIND. Dementia rates were lower than expected, but as assumed undetected 
CIND was high. The longer 3MS screening tool was found to have the greatest accuracy 
and proved 76% sensitivity and 88% specificity overall. However, because it takes 
longer (17 minutes) to complete, it is not practical to use for screening in primary care 
clinics. There was no difference in sensitivity between the Mini-Cog and the 3MS. The 
Mini-Cog performed moderately well in the detection of dementia with 76% sensitivity 
and 73% specificity. Screening is not diagnostic for diagnosis but prompts further 
evaluation. Holsinger et al. recommended more testing and more information from 
participants be gathered regarding medical record review to more accurately diagnosis 
cognitive impairment.
Holsinger et al. (2012) chose participants > 65 years old at random during 
screening interviews. A strictly demented or cognitively impaired population was not 
used, and a blinded research nurse performed the screening so that bias could be reduced. 
Using veteran clinics and with the majority of participants being male, results cannot be 
generalized as well to women. Similarly, a small range of dementia participants could 
skew test sensitivity in testing for dementia. Also, veterans often tend to have high 
education and could limit generalizability (Holsinger et al., 2012).
The current research evaluated use of screening tools to detect cognitive 
impairment and dementia in primary care clinics. The screening tools used were the 
Mini-Mental State Examination, Mini-Cog, and The Clock Drawing Test. The current 
researchers assessed whether providers are using these tools on patients older than 65
years. Interestingly, Holsinger et al.’s study also used a population of 65 years or older 
and used the Mini-Mental State Exam and the Mini-Cog. These two screening tools 
proved to be most accurate in their study.
Fowler et al. (2015) performed a study to examine the relationship between older 
primary care patients’ attitudes about dementia screening and their behavior toward 
diagnostic assessments after a positive dementia screening. Understanding the 
importance of why patients agree or disagree to diagnostic assessment after screening 
positive is critical. It is estimated that 5.3 million Americans have dementia, and 50% of 
these are never diagnosed. This proposes a major challenge for healthcare providers and 
has devastating effects on patients and their families. The stigmas surrounding cognitive 
impairment screening and subsequent dementia diagnosis could be associated with the 
high rates of undetected cognitive impairment which leads to patients not receiving the 
potential benefits of earlier recognition. No theoretical framework was mentioned in this 
study.
Fowler et al. (2015) identified the hypothesis that patients between 70 and 80 
years old would be more likely to refuse diagnostic assessment. Another hypothesis was 
that patients who acknowledged the benefits of early detection would be more likely to 
accept a follow-up evaluation after screening positive for cognitive decline.
The study population was recruited from a healthcare system known as Eskenazi 
Health in Indianapolis. The participants were 65 years or older and did not have a 
documented diagnosis of dementia at the time of recruitment. A total of 1,065 patients 
were asked to participate. O f the 1,065 participants, 550 agreed and signed informed 
consent to participate. Perceptions about dementia screening and diagnosis were 
obtained through personal encounters and measured with a questionnaire known as the
Perceptions Regarding Investigational Screening for Memory in Primary Care (PRISM- 
PC). The PRISM-PC questionnaire is composed of 50 items which examines the 
perceived harms and benefits of screening for dementia. Twelve items capture 
sociodemographic data and the study participants’ experiences with Alzheimer’s disease. 
The 38 remaining items measure participants’ perceptions of and attitudes about the 
acceptance, benefits, and harms of dementia screening and were scored on a 5-point 
Likert scale. Participants were asked to complete the PRISM-PC and then were asked 
about willingness to be screened for memory problems. Community Screening 
Instrument for Dementia (CSI-D) and the Mini-Mental State Examination (MMSE) were 
used for memory problem screening (Fowler et al., 2015).
Reverse-coding was performed on the PRISM-PC before analysis so that a higher 
score indicated stronger agreement with the items. This is done to conduct psychometric 
analyses and predict validity. The Fisher exact test was used for categorical variables and 
the two-sample t test for continuous variables to compare demographics and PRISM-PC 
domain scores. Logistic regression was used to model the association of the PRISM-PC 
domains and demographics with the refusal of diagnostic assessment. O f the 554 
participants that completed the PRISM-PC questionnaire, 497 participants agreed to 
dementia screening. Sixty-three of the 497 participants screened positive and were 
referred for a diagnostic assessment. Among the 63 participants that were referred for an 
evaluation, 21 participants agreed and went on to complete the diagnostic assessment.
The 42 participants remaining refused follow-up assessment. Among the participants 
screening positive, 61.9% were female, 55.6% were African Americans, 48% were 
widowed, and 48% lived alone. O f the 42 participants that refused diagnostic 
assessment, 25 participants lived alone and 33 participants were below 80 years of age. It
is worth mentioning that those who refused diagnostic assessment agreed more with 
statements pertaining to stigmas related to dementia on the PRISM-PC than those who 
agreed to further assessment for dementia.
Limitations of this study by Fowler et al. (2015) included its small sample size; 
however, despite the sample size, several relationships were statistically significant. 
Another limitation was the lack of ability to track those patients that screened positive to 
ascertain if they sought further medical treatment. The findings of Fowler et al. (2015) 
are important as it is known that the detection of cognitive impairment and dementia rates 
are low and patients that are cognitively impaired are not receiving the interventions and 
education that could possibly address the perceived stigmas associated with cognitive 
screening and diagnostic assessment.
Intervening on behalf of patients with possible cognitive impairment or dementia 
and changing the stigmas associated with these could potentially increase the number of 
patients becoming more receptive to cognitive impairment screening and diagnosis of 
dementia. In a study that is seeking to determine if primary care providers in Mississippi 
are screening for cognitive impairment, the current researchers hope to elucidate common 
practices that focus on the detection and diagnosis of cognitive impairment. The 
prospective gain in studying the screening practices of primary care providers is to help 
ensure that patients with possible cognitive decline do not go untreated. Examining the 
relationship between older patients’ perceptions about cognitive screening for dementia 
and their behavior toward a diagnostic assessment after a positive screening could help in 
designing a more holistic approach in caring for patients. Early intervention through 
education on cognitive impairment would potentially address the perceived stigmas 
associated with a dementia diagnosis. The Health Promotion Model was used to guide
the study on the screening practices of PCPs in Mississippi. Oe of the theoretical 
assertions of this model is that patient self-efficacy will increase as the negative 
perceived perceptions of an illness are decreased. As determined in the present study, 
providing education to older patients on the importance of early detection of cognitive 
impairment through screening could help break the barriers associated with the diagnosis 
o f any dementia-related disease.
Summary
All of the previous information that was gathered to support the basis of the 
current research project was utilized to form the tool to determine whether or not 
healthcare providers are using a screening tool for cognitive impairment. If so, which 
one are they using; if other labs, comorbidities, past medical history, and medications are 
pertinent to the evaluation and prevention of cognitive decline.
CHAPTER III 
Design and Methodology
The purpose of this study was to determine whether primary care providers are 
following the American Alzheimer’s Association guidelines related to cognitive 
impairment screening during an annual wellness visit that was put into place by the 
Patient Protection and Affordable Care Act of 2010 effective January 1, 2011. This 
chapter provides information regarding the design, setting, population, sample, method of 
data collection, and data analysis of retrospective chart reviews utilized to conduct this 
study.
Design of the Study
A descriptive, retrospective chart review was the design used in this study. 
Retrospective review was suitable for this study because information from patient charts 
is needed to determine if primary care providers are following the guidelines of the 
American Alzheimer’s Association on annual cognitive impairment screening.
Setting for Research Project
The retrospective chart reviews took place in 6 primary care clinics. The clinics 
were in rural and urban areas of north and central Mississippi. These clinics employed 
both physicians and nurse practitioners, and charts were chosen at random based on 
Medicare patients over 65 years old.
Population and Sample
A convenience sample was utilized for this study. The population of the study 
included men and women aged 65 years and older and on Medicare. This population was 
relevant to the study in that the older population develops cognitive impairment and 
should be screened for such. The Patient Protection and Affordable Care Act requires
that screening be done during an annual wellness visit in patients 65 years and older 
which validates using this specific population. Six-hundred patient charts were reviewed 
for screening, 100 from each of the 6 clinics. The patients included in this study were 
from various cultural and racial groups.
Methods of Data Collection
After obtaining approval from the Institutional Review Board (IRB) (see 
Appendix A), the research was collected using a data collection tool to easily compile 
patient information for statistical analysis. Before collecting information, a consent 
document was reviewed and signed by the office managers of the primary care clinics 
(see Appendix B). This consent was necessary to protect the privacy of patients and 
informed the clinic that findings of the research would be reported back to them if 
desired. Researchers went into the clinic during normal business hours and reviewed 100 
patient charts with the oversight of the office manager over a 4-week period in the Spring 
of 2017. The data collection tool was used to compile information pertaining to general 
demographics (e.g., age, sex, race, and ethnicity), and patient history including 
documentation of kidney function, hypertension, diabetes, vitamin deficiency, current 
medications, falls, and tobacco use (see Appendix C). The overall goal of the collection 
tool was to evaluate if healthcare providers assessed cognitive function in those 65 years 
and older.
Methods of Data Analysis
Data were subjected to analysis and then were reported using means and standard 
deviations to describe the findings of providers screening for cognitive impairment. 
Percentages were used to report healthcare providers’ compliance with current national 
guidelines. Chi-square analyses were used to derive additional data regarding relations of
chronic disease and cognitive impairment based on documented history of the patient. 
Data obtained reflected the providers’ adherence to the recommended national guidelines 
regarding the screening of cognitive impairment. Results can be used to demonstrate to 
providers how significant screening and early detection are for cognitive impairment.
CHAPTER IV 
Research Findings
The purpose of the study was to identify if primary care providers practicing in 6 
rural community-based clinics in Mississippi were screening for cognitive impairment. 
The USPSTF recommends cognitive impairment screening for all patients 65 years and 
older. Prompt detection will allow providers to put preventative practices in place, such 
as therapies and/or medication regimes, to slow the effects of cognitive impairment. 
Additional research was reviewed to determine the appropriate screening tool(s) to use in 
collecting data. Furthermore, the researchers sought to determine what intervention was 
indicated for patients who showed a decline in cognition on the screening tools.
Profile of Study Population
Data from the current research were obtained by reviewing a convenience sample 
of 100 charts at each of the 6 clinics. The sample included any patient 65 years and older 
obtaining a Medicare wellness visit while at the clinic. Data were manually extracted and 
recorded on a data collection worksheet. Demographic data included age, race, gender, 
marital and education status, and housing. The researchers recorded if cognitive 
screening was performed; and, if  performed, what cognitive screening test was used. 
Furthermore, if any patient treatment or interventions were initiated due to screening 
results, those were documented as well.
A convenience sample of 600 medical records {n = 600) 65 years and older was 
obtained from 6 separate primary care clinics in Mississippi from February-March 2017. 
All o f the patients fell within this age group as stated by the Affordable Care Act. The 
sample of 600 patients included 55.6% female patients {n = 330) and 43.8% of male
patients {n = 263). No gender was reported in 1.2% (/? = 7) of patients. The researchers 
assessed the race of the participants. African Americans comprised of 19.8% {n = 119) 
of the population studied, while 74.8% {n = 449) of the participants were white. Other
was reported for 0.8% (n = 5) of participants with 27 surveys with no race reported
Education was determined by years of formal education. Less than 12 years of education 
was obtained by 15.5% (n = 93) of the participants, while 10.5% (n = 63) had 12 or more 
years of formal education. O f the 600 participants, 74% (n = 444) of the charts did not 
have educational level recorded. The researchers recorded the living status of the 
participants. O f the 600 charts that were reviewed, 62.7% (n = 376) patients do not live 
alone, while 27.7% (n = 166) of the patients live by themselves. In addition, 1.3% (n = 
8) participants resided in a skilled facility, while 8.3% (n = 50) of charts did not report 
housing for the participants. The marital status of the participants was recorded by the 
researchers. O f the 600 participants, 49.7% {n = 298) were married, 15% (n = 90) were 
divorced, 25% (n = 150) were widowed, and 2.5% (/? = 15) were never married. Marital 
status was not documented for 7.8% (n = 47) of the participants.
Statistical Results
A total of 600 charts for patients 65 years and older presenting to the clinic for an 
annual wellness visit were chosen for a retrospective chart review. The wellness visits all 
occurred after January 1, 2011, when the recommendation by the Affordable Care Act 
included cognitive screening. The researchers compiled and organized the data using the 
data collection worksheets. Data were entered on a Microsoft Excel spreadsheet. A 
professional statistician analyzed the data using IBM SPSS statistical software, version 
22. Analyses were performed to answer the research questions. The following questions 
were investigated by the researchers.
Findings Related to the Research Questions
Research question 1. During annual wellness visits, are primary care providers 
screening Medicare patients 65 years and older to detect cognitive impairment? See 
Figure 1.
Figure 1. Screening test performed during annual wellness visit.
Research question 2. During the cognitive impairment screening, are primary 
care providers using one of the three validated patient assessment tools: the General 
Practitioner Assessment of Cognition (GPCOG), the Memory Impairment Screen (MIS), 
Mini-Mental State Exam (MMSE), or the Mini-Cog when cognitive impairment 
screening is performed? If none of the above, which assessment tool are they using? See 
Figure 2.
Figure 2. Screening tools used in the research study.
Research question 3. What interventions are put into place for patients who show 
a decline in cognition on these screening tools? See Figure 3.
Note. The plan o f  care implemented in the single case was medication for dementia.
Figure 3. Interventions for cognitive impairment.
Data Analysis
Data were collected from patient charts at 6 respective clinics located in northern 
and central Mississippi and entered on a researcher-developed data collection tool. Data 
were then entered into Microsoft Excel and analysis performed using IBM SPSS
statistical software, version 22, in an effort to accurately answer the three research 
questions.
Data analysis revealed primary care providers were noncompliant in screening for 
cognitive impairment. O f the charts reviewed, only 5 patients (0.8%) included a 
cognitive test. O f the 5 patients whose record included a cognitive test, 3 (60%) used the 
MMSE test, 1 (20%) used the Mini-Cog, and 1 (20%) did not report the test type. Of the 
5 patients whose record included a cognitive test, 2 (40%) showed a cognitive 
impairment. O f those 2, only 1 (50%) implemented a plan of care. The plan of care 
implemented in the single case was medication for dementia.
Summary Findings
Chapter IV presented the researchers’ findings from the current retrospective 
chart review of 600 patients from the 6 rural clinics in northern and central Mississippi. 
Findings from the demographics and medical history were comprised in figures for 
comparison. The results of this analysis revealed that primary healthcare providers were 
not screening for cognitive impairment and were noncompliant with the 
recommendations. There is a significant need of improvement in diagnosing and 
managing those with cognitive impairment. Due to the overall lack of primary care 
providers properly screening those for cognitive impairment, this study will provide an 
outstanding opportunity to provide education to providers about the importance of 
screening practices. With adequate screening practices in place, the number of those who 





This research study examined whether primary care providers were following 
current recommendations for screening Medicare pav. According to the Centers for 
Disease Control and prevention (CDC), over 16 million people in the United States are 
living with cognitive impairment. The predominant risk factor for cognitive impairment 
is advanced age. As America’s generation of baby boomers progress on into their senior 
years, the number of individuals suffering from cognitive impairment and related 
complications is expected to increase dramatically. Unfortunately, cognitive impairment 
goes unrecognized in 27% -81% of affected patients in primary care (Cordell et al., 
2013).
Compliance was evaluated based on the following research questions:
1. During annual wellness visits, are primary care providers screening Medicare 
patients 65 years and older to detect cognitive impairment?
2. During the cognitive impairment screening, are primary care providers using 
one of the three validated patient assessment tools: the General Practitioner 
Assessment of Cognition (GPCOG), the Memory Impairment Screen (MIS), 
Mini-Mental State Exam (MMSE), or the Mini-Cog when cognitive 
impairment screening is performed? If none of the above, which assessment 
tool are they using?
3. What interventions are put into place for patients who show a decline in 
cognition on these screening tools?
Researchers utilized Nola J. Pender’s Health Promotion Model as the theoretical 
framework to guide the current research. Included in this chapter are the following: a
summary of the findings, implications of the results, and recommendations for additional 
research.
Summary of the Findings
The initial sample consisted of 600 patient charts. The charts were obtained from 
6 primary care provider offices in the state of Mississippi. The charts of Medicare 
patients 65 years and older that had presented for their annual wellness visit were 
selected. Of the charts that were selected for review, only 5 patients received a cognitive 
impairment screening.
Patient demographies were extracted from each patient record. O f the 600 
records evaluated, 55.6% (n = 330) were female patients, 43.8% (/? = 263) were male 
patients, and 1.2% (n = 7) had no gender reported. All 600 patients were age 65 years or 
older. Their ages were categorized as follows: 65-69 years (29.5%; n = 177), 70-74 years 
(24.2%; n = 145), 75-79 years (24.2%, n = 145), and 80+ years (22.2%; n = 133). If the 
number of patients reported in a factor do not sum to the total sample size (600), the 
remaining records did not have that demographic factor reported.
Discussion of the Findings
The researchers revealed that 5 or 0.8% of the 600 patients were actually screened 
for impairment in cognition. Of the 5 patients who were cognitively screened, 3 (60%) 
used the MMSE test, 1 (20%) used the Mini-Cog, and 1 (20%) did not report the test 
type. O f the 5 patients whose records included a cognitive test, 2 (40%) showed a 
cognitive impairment. O f those 2, only 1 (50%) implemented a plan of care. The plan of 
care implemented in the single case was medications for dementia.
Limitations of the Research
The following limitations of the research design and methods of data analysis 
were identified at the conclusion of the study:
1. The sites o f data eolleetion were limited to six primary care elinies in north 
and central Mississippi.
2. Limited sample size consisting of 600 charts— 100 from each primary care 
provider’s clinic.
The researchers obtained a limited sample size of 600 charts which diminished the 
reliability of the current research. The results obtained by the researchers from such a 
limited sample size may not be indicative of all clinics screening practices across the state 
of Mississippi. To increase the reliability of the research findings related to provider 
screening practices of cognitive impairment, utilization of a greater sample size 
evaluating data from various clinics across the state would be beneficial.
Data collection was limited to primary care providers’ clinics located in the state 
of Mississippi. Restricting data collection to this one geographical location in the 
southeastern United States may not best exemplify the screening practices across the 
nation as a whole. Broadening the research to encompass other regions across the nation 
would give a better indication of the number of primary care providers that are following 
the recommendations for screening for cognitive impairment across the United States. 
Implications
Various implications were constructed following the conclusion of the current 
research. Implications include providing an area of focus for performance improvement 
in the primary care setting. Findings from the current research suggest that primary care 
providers are falling short of the suggested guidelines of cognitive impairment screening.
Clinical practice. Early detection of cognitive impairment is fundamental. 
Detection of cognitive impairment in the early stages of the disease process allows for 
application of interventions that may slow the progression of cognitive impairment and 
allow the patient to enjoy a better quality of life for an extended period of time. 
Interventions, such as management o f comorbidities and medications, can aid in slowing 
the progression from mild cognitive impairment to detrimental diseases such as 
Alzheimer’s and dementia.
By increasing primary care providers’ awareness of the recommendations related 
to screening for cognitive impairment during the annual wellness visit, the number of 
patients properly screened for cognitive impairment can be increased. This increase in 
screening would in turn result in early interventions decreasing the prevalence of 
advanced cognitive impairment-related illnesses.
Nursing education. The current research concluded that primary healthcare 
providers are failing to adequately screen patients for cognitive impairment during the 
Medicare annual wellness visit. This finding indicated that additional education is 
required to emphasize the importance of screening patients who are at increased risk for 
the development of cognitive impairment.
Primary care providers must take into account the importance of early detection 
when it comes to screening patients for cognitive impairment. Early detection of 
cognitive impairment is the key to catching the disease progression in its early stages 
where interventions, such as cognitive therapy and pharmacological treatment, are most 
beneficial. Though the absence of cognitive impairment and the eradication of the 
disease process may not be possible, the prolonging of the patient's cognition and his or 
her overall quality of life should be the goal.
The outcomes of this research study confirms the deficiency of cognitive 
impairment screening and early detection of cognitive impairment taking place during the 
Medicare annual wellness visits. The next course of action as healthcare providers and 
patient advocates should be to educate colleagues on the importance of cognitive 
impairment screening and the beneficial outcomes of early detection. Taking into 
consideration that screening practices may vary for each provider, it is important to 
encourage colleges to incorporate a recommended screening tools, such as the mini­
mental exam that can be easily conducted during the screening process.
The offices o f the providers that participated in the current research will be 
provided a copy of the research findings and results. The primary care providers can 
utilize the information obtained from the research to implement a policy or procedure 
within their clinic to increase the number of patients screened who are at risk for 
cognitive impairment.
Nursing research. Evidence-based practices are brought about as the result of 
well-designed and organized research. Recommendations for further research 
possibilities can be suggested with the conclusion of this research. First, research should 
be conducted that explores the reasons why primary care providers are not screening 
patients for cognitive impairment. These reasons could include lack of education 
concerning the current guidelines. Consideration can also be given to the possibility that 
consumers of Medicare are not aware of certain benefits afforded to them. Research can 
be conducted to determine if Medicare beneficiaries are informed or understand these 
benefits. Replication of the current research using a larger sample and a more diverse 
demographic range should be done to determine if cognitive impairment screening 
practices are the same in other regions or are they specific to a certain area.
Nursing theory. Nola Pender’s Health Promotion Model was selected by the 
researchers as the theoretical foundation for the current research. Pender believes the 
patient should play an active role in managing his or her health by desiring to change or 
alter certain lifestyles that may contribute to disease. Recognizing any perceived barriers 
can be a positive step toward motivating the patient to accept a diagnosis o f cognitive 
impairment without the fear or stigma related to changes in cognition. Nola Pender’s 
view also included the concept that past behavior, cultural traditions, and family 
traditions can impact a person's ability to engage in health-promoting behaviors. The 
assumption that healthcare providers are part of the patient's interpersonal environment 
opens up a wide avenue that allows the practitioner to become personally involved with 
the patient. Her HPM provides healthcare providers with a tool that helps them to 
understand how the consumer can be motivated to attain better health (Alligood, 20141). 
The results of this study will aid in the development o f methods to assist the practitioner 
in recognizing cognitive impairment as part of the patient’s health promotion and 
prevention.
Conclusion
The purpose of this research was to determine if primary health care providers are 
screening Medicare patients 65 years and older during their annual wellness visit for 
cognitive impairment. The study further evaluated the presence of comorbidities and 
associated factors increasing a patient’s risk for cognitive impairment. According to the 
results of this study, cognitive impairment screening is not being performed on Medicare 
patients during annual wellness visits. Since cognitive decline can ultimately progress to 
dementia or Alzheimer's dementia, it is imperative that healthcare providers detect 
changes in the patient's cognition so that appropriate treatments can be initiated early in
the disease process. It was also found that other factors can contribute to changes in 
mental status and cognition, such as medications, smoking. Vitamin deficiencies, and 
chronic disease. Knowing the medical history of their patients and performing the 
necessary screening to detect certain deficiencies can assist primary care providers in 
promoting the importance of cognitive screening and relaying this knowledge to their 
patients.
Recommendations
Based on the results o f the current research, the following recommendations were 
made for primary care providers:
1. Increase providers’ compliance of screening patients for cognitive impairment 
according to recommendations.
2. Educate providers on the recommended screening tools available for detection 
of cognitive impairment.
3. Increase providers’ awareness of comorbidities and risk factors that increase 
the likelihood that a patient will develop cognitive impairment.
4. Increase the public’s awareness of cognitive impairment and the need for 
screening to detect cognitive impairment in its early stages.
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understand that the results of the study will be made available to me at the end of project.
Name and Title Date
APPENDIX C 











Race or ethnicity: ___White
Education (years): ___0-11 ___
Housing:  Living alone  Does not live alone _





Polypharmacy (> 5 meds RX or OTC):
Labs within the last 3 years: ___ Vitamin D
Polypharmacy (> 5 meds RX and/or O TC):___
Any opioid use?  Yes
Any NSAIDS use?  Yes
Currently taking anticholinergics?  Yes
Diagnosed with any of the following?  HTN _
Was cognitive test performed? ___Yes __












If cognitive impairment was detected, was a plan of care implemented? Yes No
If yes, what was implemented?
Neuro referral Social services Medications for dementia
